A new method for investigating bioequivalence of inhaled formulations: A pilot study on salbutamol
Conclusion: EBC data of the present work may be considered as a reliable source for assessment of the BE studies of orally inhaled drug formulations. However, more detailed investigations employing larger sample sizes and more formulations are required to provide more evidence for the proposed method of BE assay.PMID:37206631 | PMC:PMC10188931 | DOI:10.3389/jpps.2023.11466 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 19, 2023 Category: Drugs & Pharmacology Authors: Homa Rezaei Maryam Khoubnasabjafari Vahid Jouyban-Gharamaleki Hamed Hamishehkar Mohammad Reza Afshar Mogaddam Elaheh Rahimpour Reza Mehvar Abolghasem Jouyban Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.PMID:37122387 | PMC:PMC10130193 | DOI:10.3389/jpps.2023.11263 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - May 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tanaka Takenao Koseki Kohsuke Sekido Masashi Kimata Yasuki Ito Shigeki Yamada Source Type: research
